Category: Rahul Singhvi

Novavax's VLP Technology is selected by spanish government for Comprehensive Flu Vaccine Solution in Spain

June 30, 2009 by srrpenna

ROCKVILLE, Md., June 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (NASDAQ: NVAX) announced today its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain. ROVI will use the VLP technology to create a comprehensive influenza vaccine solution for the Spanish government under a new 60 million-euro program sponsored and led by the Spanish Ministry of Health and other government groups to develop pandemic and seasonal flu vaccines and establish its only in-border facility.